Similar articles for PMID: 18809245

Year	Number of Results
1985	1
1988	1
1989	3
1990	1
1996	2
1997	1
1999	2
2001	1
2007	6
2008	14
2009	7
2010	5
2011	3
2012	2
2013	5
2014	7
2015	4
2016	6
2017	4
2018	1
2020	1
2023	1
2024	0

1

Ghosh N, Matsui W. Ghosh N, et al. Cancer Lett. 2009 May 8;277(1):1-7. doi: 10.1016/j.canlet.2008.08.005. Epub 2008 Sep 21. Cancer Lett. 2009. PMID: 18809245 Free PMC article. Review.

2

Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.

Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, Borrello I, McNiece I, Lin L, Ambinder RF, Peacock C, Watkins DN, Huff CA, Jones RJ. Matsui W, et al. Cancer Res. 2008 Jan 1;68(1):190-7. doi: 10.1158/0008-5472.CAN-07-3096. Cancer Res. 2008. PMID: 18172311 Free PMC article.

3

Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?

Franqui-Machin R, Wendlandt EB, Janz S, Zhan F, Tricot G. Franqui-Machin R, et al. Oncotarget. 2015 Dec 1;6(38):40496-506. doi: 10.18632/oncotarget.5800. Oncotarget. 2015. PMID: 26415231 Free PMC article. Review.

4

The myeloma stem cell concept, revisited: from phenomenology to operational terms.

Johnsen HE, Bøgsted M, Schmitz A, Bødker JS, El-Galaly TC, Johansen P, Valent P, Zojer N, Van Valckenborgh E, Vanderkerken K, van Duin M, Sonneveld P, Perez-Andres M, Orfao A, Dybkær K. Johnsen HE, et al. Haematologica. 2016 Dec;101(12):1451-1459. doi: 10.3324/haematol.2015.138826. Epub 2016 Nov 10. Haematologica. 2016. PMID: 27903712 Free PMC article. Review.

5

Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma.

Issa ME, Takhsha FS, Chirumamilla CS, Perez-Novo C, Vanden Berghe W, Cuendet M. Issa ME, et al. Clin Epigenetics. 2017 Feb 10;9:17. doi: 10.1186/s13148-017-0319-5. eCollection 2017. Clin Epigenetics. 2017. PMID: 28203307 Free PMC article. Review.

6

Concise review: Defining and targeting myeloma stem cell-like cells.

Abe M, Harada T, Matsumoto T. Abe M, et al. Stem Cells. 2014 May;32(5):1067-73. doi: 10.1002/stem.1643. Stem Cells. 2014. PMID: 24449391 Review.

7

Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells.

Stefka AT, Park JH, Matsuo Y, Chung S, Nakamura Y, Jakubowiak AJ, Rosebeck S. Stefka AT, et al. Blood Cancer J. 2016 Aug 19;6(8):e460. doi: 10.1038/bcj.2016.71. Blood Cancer J. 2016. PMID: 27540718 Free PMC article. No abstract available.

8

Cancer stem cells: controversies in multiple myeloma.

Brennan SK, Matsui W. Brennan SK, et al. J Mol Med (Berl). 2009 Nov;87(11):1079-85. doi: 10.1007/s00109-009-0531-7. Epub 2009 Sep 17. J Mol Med (Berl). 2009. PMID: 19760278 Free PMC article. Review.

9

IQGAP1 Scaffold-MAP Kinase Interactions Enhance Multiple Myeloma Clonogenic Growth and Self-Renewal.

Gocke CB, McMillan R, Wang Q, Begum A, Penchev VR, Ali SA, Borrello I, Huff CA, Matsui W. Gocke CB, et al. Mol Cancer Ther. 2016 Nov;15(11):2733-2739. doi: 10.1158/1535-7163.MCT-16-0323. Epub 2016 Aug 29. Mol Cancer Ther. 2016. PMID: 27573425 Free PMC article.

10

Tumorigenesis: Testing ground for cancer stem cells.

Delude C. Delude C. Nature. 2011 Dec 14;480(7377):S43-5. doi: 10.1038/480S43a. Nature. 2011. PMID: 22169801 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

70 results

Results by year